Conference Call Scheduled for today, February 14, 2023 at 5:00pm ET
GARDNER, Mass., Feb. 14, 2023 /PRNewswire/ -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its second quarter fiscal year 2023.
Second quarter fiscal 2023 highlights:
- Revenue for the quarter ended December 31, 2022, increased 51% to $5.89 million, a new quarterly record, compared to $3.90 million in the same quarter of the previous fiscal year.
- Included in revenue for the quarter ended December 31, 2022 was a one-time sale of $600,000 of technology rights relating to a medical device instrument developed for a customer. Without this one-time sale, revenue for the quarter would have been $5.29 million, a 36% year-over-year increase.
- Gross margin for the quarter ended December 31, 2022 was 46% compared to 29% in the same quarter of the previous year. Excluding contributions from the one-time sale of technology rights, gross margin would have been 40% for the quarter ended December 31, 2022 .
- Net income for the quarter was $634,420 which compared to net loss of $(507,013) in the same quarter of the previous year. Excluding contributions from the one-time sale of technology rights, net income would have been $34,420 for the quarter ended December 31, 2022 .
- Adjusted EBITDA, defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation and other income, was $993,449 for the quarter ended December 31, 2022, compared to ($72,456) in the same quarter of the previous year. Excluding contributions from the one-time sale of technology rights, Adjusted EBITDA would have been $393,449 for the quarter ended December 31, 2022 .
Recent additional highlights:
- In November 2022, the Company listed on the Nasdaq Capital Market.
- In December 2022, the Company announced the receipt of an initial product development order for a next generation single-use urology program totaling approximately $750,000 from an established medical device company leveraging the Company's unique expertise in micro-optics, medical systems, and digital imaging.
- In December 2022, the Company announced the receipt of a follow-on production order totaling approximately $2.6 million from a major US defense contractor, to meet increased demand for a highly complex optical assembly.
- In January 2023, the Company announced the receipt of a follow-on production order totaling approximately $2.3 million from a large medical device company for an otoscopy application to meet enhanced demand for the product.
- In February 2023, the Company announced its engagement into a production and technology license agreement under which the Company expects to manufacture or be paid royalties on a single-use product jointly developed by the Company and its customer.
Precision Optics' CEO, Joseph Forkey, commented, "The second quarter of fiscal 2023 was a quarter of many milestones for Precision Optics, culminating with record quarterly revenues, positive net income, and the Company's listing on the Nasdaq Capital Markets. Further, we received a number of new orders over the past few months that position us well as we enter the second half of the fiscal year, including a new urology application, and follow-on production orders from a major US defense contractor as well as a large medical device company. Notably, we also signed a key agreement with a customer with whom we have been developing a single-use product for use in the ophthalmic market. As part of this agreement, we received a one-time non-refundable payment of $600,000 that contributed to our revenue for the quarter. Even without this payment we would have had record revenues, net income, and adjusted EBITDA.
"Our development pipeline remains robust, with a number of new projects advancing through the pipeline positioning us well for the future. Operationally, we achieved our highest gross margin in the company's recent history which, excluding the one-time payment for technology rights, was slightly greater than 40% during the quarter. We continue to gain manufacturing efficiencies through absorption of production resources and we are limiting the increase in operating expenses to those targeting growth, all of which has translated into positive net income and significant improvement in our adjusted EBITDA. These improvements are beginning to demonstrate our stated goal of translating recent top-line revenue increases to higher overall profitability. All told, I am very pleased with our second quarter results and look forward to ongoing progress throughout the year."
The following table summarizes the second quarter (unaudited) results for the periods ended December 31, 2022 and 2021: Note: the Common Share figures in this table reflect post-split figures.
Three Months | Six Months | |||||
Ended December 31, | Ended December 31, | |||||
2022 | 2021 | 2022 | 2021 | |||
Revenues | $ 5,886,961 | $ 3,897,041 | $ 10,972,262 | $ 6,233,385 | ||
Gross Profit | 2,725,244 | 1,119,582 | 4,449,878 | 1,758,614 | ||
Stock Compensation Expenses | 244,786 | 131,656 | 319,776 | 453,693 | ||
Business Acquisition Expenses | 0 | (10,049) | 0 | 162,125 | ||
Other | 1,783,621 | 1,458,325 | 3,449,874 | 2,175,098 | ||
Total Operating Expenses | 2,028,407 | 1,579,932 | 3,769,650 | 2,790,916 | ||
Operating Income (Loss) | 696,817 | (460,350) | 680,228 | (1,032,302) | ||
Net Income (Loss) | 634,420 | (507,013) | 560,909 | (1,083,814) | ||
Income (Loss) per Share | ||||||
Basic | $ 0.11 | $ (0.09) | $ 0.10 | $ (0.22) | ||
Fully Diluted | $ 0.11 | $ (0.09) | $ 0.09 | $ (0.22) | ||
Weighted Average Common Shares Outstanding | ||||||
Basic | 5,638,302 | 5,526,413 | 5,638,302 | 4,976,923 | ||
Fully Diluted | 5,935,911 | 5,526,413 | 5,937,471 | 4,976,923 | ||
Conference Call Details
Date and Time: Tuesday, February 14, 2023, at 5:00pm ET
Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/X13yO6a8LAV.
Replay: A teleconference replay of the call will be available until February 21, 2023 at (877) 344-7529 or (412) 317-0088, replay access code 4249407. A webcast replay will be available at https://app.webinar.net/X13yO6a8LAV.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.
Non-GAAP Financial Measures
Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America ("non-GAAP"). The non-GAAP financial measure is adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). Adjusted EBITDA also excludes from Net income from continuing operations the effect of Stock-based compensation, Restructuring and other acquisition related expenses.
This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.
About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.
Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Phoenix | New York
Telephone: 602-889-9700
[email protected]
Following are the Company's Consolidated Balance Sheets at December 31, 2022 and June 30, 2022, and Statements of Operations, for the three and six months ended December 31, 2022 and 2021:
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES | ||||||||
December 31, | June 30, | |||||||
2022 | 2022 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 381,318 | $ | 605,749 | ||||
Accounts receivable, net of allowance for doubtful accounts of $72,343 at December 31, 2022 and $44,135 at June 30, 2022 | 4,032,522 | 2,663,872 | ||||||
Inventories | 2,846,975 | 3,079,938 | ||||||
Prepaid expenses | 213,177 | 213,448 | ||||||
Total current assets | 7,473,992 | 6,563,007 | ||||||
Fixed Assets: | ||||||||
Machinery and equipment | 3,222,406 | 3,215,412 | ||||||
Leasehold improvements | 795,572 | 786,112 | ||||||
Furniture and fixtures | 227,599 | 219,999 | ||||||
Total fixed assets | 4,245,577 | 4,221,523 | ||||||
Less-Accumulated depreciation and amortization | 3,756,593 | 3,651,843 | ||||||
Net fixed assets | 488,984 | 569,680 | ||||||
Operating lease right-to-use asset | 439,074 | 517,725 | ||||||
Patents, net | 242,981 | 229,398 | ||||||
Goodwill | 8,824,210 | 8,824,210 | ||||||
TOTAL ASSETS | $ | 17,469,241 | $ | 16,704,020 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Current portion of financing lease obligation | $ | 41,938 | $ | 40,705 | ||||
Current maturities of long-term debt | 371,429 | 367,714 | ||||||
Current portion of acquisition earn out liabilities | 889,525 | 166,667 | ||||||
Accounts payable | 2,244,270 | 2,239,175 | ||||||
Contract liabilities | 794,981 | 905,113 | ||||||
Accrued compensation and other | 971,864 | 716,702 | ||||||
Operating lease liability | 163,984 | 150,565 | ||||||
Total current liabilities | 5,477,991 | 4,586,641 | ||||||
Financing lease obligation, net of current portion | 90,409 | 111,691 | ||||||
Long-term debt, net of current maturities and debt issuance costs | 1,773,571 | 1,961,141 | ||||||
Acquisition earn out liability, net of current portion | - | 705,892 | ||||||
Operating lease liability, net of current portion | 275,090 | 367,160 | ||||||
Stockholders' Equity: | ||||||||
Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding - 5,638,302 shares at December 31, 2022 and June 30, 2022 | 56,383 | 56,383 | ||||||
Additional paid-in capital | 57,329,282 | 57,009,506 | ||||||
Accumulated deficit | (47,533,485) | (48,094,394) | ||||||
Total stockholders' equity | 9,852,180 | 8,971,495 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 17,469,241 | $ | 16,704,020 | ||||
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES | ||||||||||||||||
Three Months | Six Months | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Revenues | $ | 5,886,961 | $ | 3,897,041 | $ | 10,972,262 | $ | 6,233,385 | ||||||||
Cost of goods sold | 3,161,737 | 2,777,459 | 6,522,384 | 4,474,771 | ||||||||||||
Gross Profit | 2,725,224 | 1,119,582 | 4,449,878 | 1,758,614 | ||||||||||||
Research and Development Expenses | 208,666 | 113,164 | 454,143 | 218,350 | ||||||||||||
Selling, General and Administrative Expenses | 1,819,741 | 1,466,768 | 3,315,507 | 2,400,392 | ||||||||||||
Business Acquisition Expenses | - | - | - | 172,174 | ||||||||||||
Total Operating Expenses | 2,028,407 | 1,579,932 | 3,769,650 | 2,790,916 | ||||||||||||
Operating Income (Loss) | 696,817 | (460,350) | 680,228 | (1,032,302) | ||||||||||||
Interest (Expense) Income, net | (62,397) | (46,663) | (119,319) | (51,512) | ||||||||||||
Net Income (Loss) | $ | 634,420 | $ | (507,013) | $ | 560,909 | $ | (1,083,814) | ||||||||
Income (Loss) Per Share: | ||||||||||||||||
Basic | $ | 0.11 | $ | (0.09) | $ | 0.10 | $ | (0.22) | ||||||||
Fully Diluted | $ | 0.11 | $ | (0.09) | $ | 0.09 | $ | (0.22) | ||||||||
Weighted Average Common Shares Outstanding: | ||||||||||||||||
Basic | 5,638,302 | 5,526,413 | 5,638,302 | 4,976,923 | ||||||||||||
Fully Diluted | 5,935,911 | 5,526,413 | 5,937,471 | 4,976,923 | ||||||||||||
Note: The Common Shares in this table reflect shares on a post reverse split basis for all periods presented. |
PRECISION OPTICS CORPORATION, INC AND SUBSIDIARIES | ||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | ||||||||
ADJUSTED EBITDA | ||||||||
Three Months Ended | Six Months Ended | |||||||
December 31, | December 31, | |||||||
2022 | 2021 | 2022 | 2021 | |||||
Net income from Continuing operations (GAAP) | $ 634,420 | $ (507,013) | $ 560,909 | $ (1,083,814) | ||||
Stock Based Compensation | 244,786 | 350,452 | 319,776 | 510,523 | ||||
Depreciation & Amortization | 51,846 | 47,391 | 103,929 | 89,682 | ||||
Interest Expense | 62,397 | 46,763 | 119,319 | 51,612 | ||||
Acquisition Expense | 0 | (10,049) | 0 | 162,125 | ||||
Adjusted EBITDA (non-GAAP) | $ 993,449 | $ (72,456) | $ 1,103,933 | $ (269,872) | ||||
SOURCE Precision Optics Corporation
